Emergence of resistance to azithromycin-atovaquone in immunocompromised patients with babesia microti infection

Clinical Infectious Diseases

Volumn 50, Issue 3, 2010, Pages 381-386

  Wormser, Gary P ^a   Prasad, Aakanksha ^a   Neuhaus, Ellen ^d   Joshi, Samit ^e   Nowakowski, John ^a   Nelson, John ^b   Mittleman, Abraham ^b   Aguero Rosenfeld, Maria ^c   Topal, Jeffrey ^e   Krause, Peter J ^e  

^a Divisions of Infectious Diseases   (United States)

^b Division of Hematology/Oncology   (United States)

^c NEW YORK MEDICAL COLLEGE   (United States)

^d Rockville General Hospital   (United States)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATOVAQUONE; ATOVAQUONE PLUS PROGUANIL; AZITHROMYCIN; CLINDAMYCIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DOXORUBICIN; DOXYCYCLINE; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN; PREDNISONE; QUININE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ANAMNESIS; ANEMIA; ANTIBIOTIC RESISTANCE; ARTICLE; BABESIA MICROTI; BABESIOSIS; CASE REPORT; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG FEVER; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GRANULOCYTOPENIA; HEARING LOSS; HISTOPATHOLOGY; HUMAN; IMMUNOCOMPROMISED PATIENT; LABORATORY TEST; MALE; PARASITEMIA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RELAPSE; THROMBOCYTOPENIA;

AGED, 80 AND OVER; ANIMALS; ANTIPROTOZOAL AGENTS; ATOVAQUONE; AZITHROMYCIN; BABESIA MICROTI; BABESIOSIS; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; MALE; MIDDLE AGED; PARASITEMIA;

EID: 75749115914     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/649859     Document Type: Article

References (18)

1. Wormser GP, Dattwyler RJ, Shapiro ED, et al. The clinical assessment, treatment and prevention of Lyme disease, human granulocytic ana-plasmosis, and babesiosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2006;43:1089-1134.
2. Krause PJ, Lepore T, Sikand VK, et al. Atovaquone and azithromycin for the treatment of babesiosis. N Engl J Med 2000;343:1454-1458.
3. 3. Krause PJ, Gewurz BE, Hill D, et al. Persistent and relapsing babesiosis in immunocompromised patients. Clin Infect Dis 2008;46:370-376. (Pubitemid 351263520)
4. 4. Krause PJ, Telford SR III, Spielman A, et al. Concurrent Lyme disease and human babesiosis: evidence for increased severity and duration of illness. JAMA 1996;275:1657-1660. (Pubitemid 26175813)
5. Krause PJ, Spielman A, Telford SR III, et al. Persistent parasitemia after acute babesiosis. N Engl J Med 1998;339:160-165.
6. Vyas JM, Telford SR, Robbins GK. Treatment of refractory Babesia microti infection with atovaquone-proguanil in an HIV-infected pa-tient: case report. Clin Infect Dis 2007;45:1588-1590.
7. Wittner M, Lederman J, Tanowitz HB, Rosenbaum GS, Weiss LM. Atovaquone in the treatment of Babesia microti infections in hamsters. Am J Trop Med Hyg 1996;55:219-222.
8. Gray JS, Pudney M. Activity of atovaquone against Babesia microti in the Mongolian gerbil, Meriones unguiculatus. J Parasitol 1999;85:723-728.
9. Weiss LM. Babesiosis in humans: a treatment review. Expert Opin Phar-macother 2002;3:1109-1115.
10. Hughes WT, Oz HS. Successful prevention and treatment of babesiosis with atovaquone. J Infect Dis 1995;172:1042-1046.
11. Miller LH, Neva F, Gill F. Failure of chloroquine in human babesiosis (Babesia microti): case report and chemotherapeutic trials in hamsters. Ann Intern. Med 1978;88:200-202.
12. Weiss LM, Wittner M, Wasserman S, Oz HS, Retsema J, Tanowitz HB. Efficacy of azithromycin for treating Babesia microti infection in the hamster model. J Infect Dis 1993; 168:1289-1292.
13. Rowin KS, Tanowitz HB, Wittner M. Therapy of experimental babe-siosis. Ann Intern Med 1982;97:556-558.
14. Homer MJ, Aguilar-Delfin I, Telford SR III, Krause PJ, Persing DH. Babesiosis. Clin Microbiol Rev 2000; 13:451-469.
15. Clawson ML, Paciorkowski N, Rajan TV, et al. Cellular immunity, but not gamma interferon, is essential for resolution of Babesia microti infection in BALB/c mice. Infect Immun 2002; 70:5304-5306.
16. Liossis S-NC, Sfikakis PP. Rituximab-induced B cell depletion in au-toimmune diseases: potential effects on. T cells. Clin Immunol 2008; 127:280-285.
17. 17. Ringwald P, Basco LK. Comparison of in vivo and in vitro tests of resistance in patients treated with chloroquine in Yaounde, Cameroon. Bull WHO 1999; 77:34-43. (Pubitemid 29282137)
18. 18. Griffith KS, Lewis LS, Mali S, et al. Treatment of malaria in the United States: a systematic review. JAMA 2007; 297:2264-2277. (Pubitemid 47018065)